Financial Instruments and Fair Value Measurements (Tables)

12 Months Ended

Sep. 25, 2015

Schedule of Fair Value of Assets and Liabilities Measured on a Recurring Basis

The following tables provide a summary of the significant assets and liabilities that are measured at fair value on a recurring basis at the end of each period:



	September 25, 2015		Quoted Prices in Active Markets for Identical Assets (Level 1)		Significant Other Observable Inputs (Level 2)		Significant Unobservable Inputs (Level 3)
Assets:
Debt and equity securities held in rabbi trusts	$	34.6	$	24.2	$	10.4	$	—
	$	34.6	$	24.2	$	10.4	$	—
Liabilities:
Deferred compensation liabilities	$	20.0	$	—	$	20.0	$	—
Contingent consideration and acquired contingent liabilities	174.6		—		—		174.6
Foreign exchange forward and option contracts	3.3		3.3		—		—
	$	197.9	$	3.3	$	20.0	$	174.6



	September 26, 2014		Quoted Prices in Active Markets for Identical Assets (Level 1)		Significant Other Observable Inputs (Level 2)		Significant Unobservable Inputs (Level 3)
Assets:
Debt and equity securities held in rabbi trusts	$	35.7	$	22.9	$	12.8	$	—
	$	35.7	$	22.9	$	12.8	$	—
Liabilities:
Deferred compensation liabilities	$	15.0	$	—	$	15.0	$	—
Contingent consideration and acquired contingent liabilities	202.8		—		—		202.8
Foreign exchange forward and option contracts	0.2		0.2		—		—
	$	218.0	$	0.2	$	15.0	$	202.8

Schedule of Reconciliation of Changes in Fair Value of Contingent Consideration



Balance at September 26, 2014	$	202.8
Payments	(29.0		)
Accretion expense	7.5
Effect of currency rate change	(6.7		)
Balance at September 25, 2015	$	174.6

Schedule of Carrying Amount and Fair Value of Long-term Debt

The following table presents the carrying values and estimated fair values of the Company's long-term debt, excluding capital leases, as of the end of each period:



	September 25, 2015				September 26, 2014
	Carrying Value		Fair Value		Carrying Value		Fair Value
Variable rate receivable securitization	$	153.0	$	153.0	$	150.0	$	150.0
2.85% term loan due April 2016	—		—		3.1		3.1
3.50% notes due April 2018	300.0		294.3		300.0		290.2
4.875% notes due April 2020	700.0		684.1		—		—
Term loans due March 2021	1,978.5		1,966.5		1,996.7		1,970.4
4.00% term loan due February 2022	7.9		7.9		10.8		10.8
9.50% debentures due May 2022	10.4		13.0		10.4		14.2
5.75% notes due August 2022	900.0		876.1		900.0		907.3
8.00% debentures due March 2023	4.4		5.3		8.0		10.2
4.75% notes due April 2023	600.0		539.6		600.0		563.8
5.625% notes due October 2023	750.0		705.2		—		—
5.50% notes due April 2025	700.0		646.0		—		—
Revolving credit facility	500.0		500.0		—		—

Schedules of Concentration of Risk

The following table shows net sales attributable to distributors that accounted for 10% or more of the Company's total net sales:



	Fiscal Year
	2015		2014		2013
CuraScript, Inc.	31	%	6	%	—	%
McKesson Corporation	18	%	21	%	19	%
Cardinal Health, Inc.	14	%	22	%	24	%
AmerisourceBergen Corporation	9	%	14	%	11	%

The following table shows accounts receivable attributable to distributors that accounted for 10% or more of the Company's gross accounts receivable at the end of each period:



	September 25, 2015		September 26, 2014
McKesson Corporation	24	%	27	%
CuraScript, Inc.	16	%	15	%
Cardinal Health, Inc.	13	%	18	%
AmerisourceBergen Corporation	12	%	14	%

The following table shows net sales attributable to products that accounted for 10% or more of the Company's total net sales:



	Fiscal Year
	2015		2014		2013
Acthar	31	%	6	%	—	%
Acetaminophen products (API)	6	%	9	%	13	%
Methylphenidate ER	4	%	10	%	9	%